European Union restrictions on pharmaceutical companies communicating directly with patients will be reviewed by regulators planning new draft rules, EU officials said. The European Medicines Agency received a letter from the European Commission saying that it will review the policy, said Peter Arlett, head of the agency’s drug safety unit, at a meeting in London today. The rules are intended to make regulations more uniform across the 27-nation bloc. “The European Commission will revise the proposals to clarify and harmonize the rules in what companies can and can’t say to patients,” Arlett said in an interview. It’s uncertain whether restrictions will be lifted, he said.
